Bristol-Myers Squibb Company

Bristol Myers Squibb is a global biopharmaceutical company dedicated to the discovery, development, and delivery of innovative medicines that help patients overcome serious diseases. Headquartered in Princeton, New Jersey, the company focuses its efforts on addressing significant unmet medical needs worldwide.

The company's portfolio includes key products such as Eliquis (apixaban) for atrial fibrillation, Opdivo (nivolumab) and Yervoy (ipilimumab) for various cancers, Revlimid (lenalidomide) and Pomalyst/Imnovid (pomalidomide) for multiple myeloma, and Orencia (abatacept) for autoimmune diseases. Bristol Myers Squibb primarily operates within the market segments of oncology, hematology, immunology, and cardiovascular conditions, with a strong emphasis on research and development.

Chris Boerner serves as the Board Chair and Chief Executive Officer, having assumed the role in November 2023. In the first quarter of 2026, Bristol Myers Squibb reported revenues of $11.5 billion, marking a 3% increase from the same period in 2025. The company continues to navigate patent expiration risks by expanding indications for existing therapies and advancing a robust pipeline of late-stage assets, while also positioning new treatments like Cobenfy for conditions such as Alzheimer's psychosis.